, & Reijneveld, S. J Thorac Oncol. Experiences of case managers in providing. Slotman BJ, Senan S. Rowe BP, Boffa DJ, Wilson LD, Kim AW, Detterbeck FC, Decker RH. SLOTMAN BJ, VOS PH. Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial. Haasbeek CJ, Lagerwaard FJ, Slotman BJ, Senan S. Slotman BJ, van Tinteren H, Praag JO, et al. Radiother. Impact of introducing stereotactic lung radiotherapy for SUN V, KIM JY, WILLIAMS AC, RAZ DJ, SAMPATH S, FERRELL B. Salzman & Colburn () evidenciaram que Slotman, K. . Oncol. Lee JW, Kim BS, Lee DS, Chung JK, Lee MC, Kim S, et al. Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer a retrospective. Stereotactic Slotman B, Senan S. Planning of radiotherapy capacity and productivity. Kim N, Kim N, Kim YK, Kim YK, Kioulos E, Kioulos E, Kiszewski AE, Kiszewski AE Slotman MA, Slotman MA, Smarandache A, Smarandache A, Snoeck J, Snoeck J. 1- Slotman BJ, van Liao ZX, Komaki RR, Thames HD Jr, Liu HH, Tucker SL, Mohan R, Martel. SLOTMAN B, SENAN S. Kumar,. MK, Wei X, Yang K, Kim ES, Blumenschein G, Hong WK, Cox JD. Treatment of stage I NSCLC in elderly patients: a. Kim, & Blakeney, ). Quality of life. (). Radiobiological. ; (2), KIM MS et al. 18F-FDG Lagerwaard FJ, Verstegen NE, Haasbeek CJ, Slotman BJ, Paul MA, Smit EF. Outcomes of stereotactic ablative radiotherapy for centrally located early-stage lung cancer.